1
|
Brozovich AA, Lenna S, Brenner C, Serpelloni S, Paradiso F, McCulloch P, Yustein JT, Weiner B, Taraballi F. Systemic Cisplatin Does Not Affect the Bone Regeneration Process in a Critical Size Defect Murine Model. ACS Biomater Sci Eng 2024; 10:1646-1660. [PMID: 38350651 PMCID: PMC10936525 DOI: 10.1021/acsbiomaterials.3c01266] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/01/2023] [Revised: 01/11/2024] [Accepted: 01/12/2024] [Indexed: 02/15/2024]
Abstract
Osteosarcoma (OS) is the most common primary malignant bone tumor, and the current standard of care for OS includes neoadjuvant chemotherapy, followed by an R0 surgical resection of the primary tumor, and then postsurgical adjuvant chemotherapy. Bone reconstruction following OS resection is particularly challenging due to the size of the bone voids and because patients are treated with adjuvant and neoadjuvant systemic chemotherapy, which theoretically could impact bone formation. We hypothesized that an osteogenic material could be used in order to induce bone regeneration when adjuvant or neoadjuvant chemotherapy is given. We utilized a biomimetic, biodegradable magnesium-doped hydroxyapatite/type I collagen composite material (MHA/Coll) to promote bone regeneration in the presence of systemic chemotherapy in a murine critical size defect model. We found that in the presence of neoadjuvant or adjuvant chemotherapy, MHA/Coll is able to enhance and increase bone formation in a murine critical size defect model (11.16 ± 2.55 or 13.80 ± 3.18 versus 8.70 ± 0.81 mm3) for pre-op cisplatin + MHA/Coll (p-value = 0.1639) and MHA/Coll + post-op cisplatin (p-value = 0.1538), respectively, at 12 weeks. These findings indicate that neoadjuvant and adjuvant chemotherapy will not affect the ability of a biomimetic scaffold to regenerate bone to repair bone voids in OS patients. This preliminary data demonstrates that bone regeneration can occur in the presence of chemotherapy, suggesting that there may not be a necessity to modify the current standard of care concerning neoadjuvant and adjuvant chemotherapy for the treatment of metastatic sites or micrometastases.
Collapse
Affiliation(s)
- Ava A. Brozovich
- Department
of Orthopedics, Ohio State University, Wexner
Medical Center, 410 W.
10th Avenue, Columbus, Ohio 43210, United States
- Center
for Musculoskeletal Regeneration, Houston
Methodist Research Institute, Houston, Texas 77030, United States
- Houston
Methodist Orthopedics & Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States
| | - Stefania Lenna
- Center
for Musculoskeletal Regeneration, Houston
Methodist Research Institute, Houston, Texas 77030, United States
- Houston
Methodist Orthopedics & Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States
| | - Carson Brenner
- Department
of Orthopedics, Ohio State University, Wexner
Medical Center, 410 W.
10th Avenue, Columbus, Ohio 43210, United States
| | - Stefano Serpelloni
- Center
for Musculoskeletal Regeneration, Houston
Methodist Research Institute, Houston, Texas 77030, United States
- Houston
Methodist Orthopedics & Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States
- Department
of Electronics, Informatics, and Bioengineering (DEIB), Politecnico di Milano, Milan 20133, Italy
| | - Francesca Paradiso
- Center
for Musculoskeletal Regeneration, Houston
Methodist Research Institute, Houston, Texas 77030, United States
- Houston
Methodist Orthopedics & Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States
| | - Patrick McCulloch
- Houston
Methodist Orthopedics & Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States
| | - Jason T. Yustein
- Aflac
Cancer and Blood Disorders Center, Emory
University, Atlanta, Georgia 30322, United States
| | - Bradley Weiner
- Center
for Musculoskeletal Regeneration, Houston
Methodist Research Institute, Houston, Texas 77030, United States
- Houston
Methodist Orthopedics & Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States
| | - Francesca Taraballi
- Center
for Musculoskeletal Regeneration, Houston
Methodist Research Institute, Houston, Texas 77030, United States
- Houston
Methodist Orthopedics & Sports Medicine, Houston Methodist Hospital, Houston, Texas 77030, United States
| |
Collapse
|
2
|
Zhang Q, Wang L, Cao L, Wei T. Novel circular RNA circATRNL1 accelerates the osteosarcoma aerobic glycolysis through targeting miR-409-3p/LDHA. Bioengineered 2021; 12:9965-9975. [PMID: 34635009 PMCID: PMC8809938 DOI: 10.1080/21655979.2021.1985343] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/11/2021] [Revised: 09/21/2021] [Accepted: 09/21/2021] [Indexed: 12/15/2022] Open
Abstract
In recent researches, circular RNAs (circRNAs) have been shown to exert critical functions in osteosarcoma biology. Nevertheless, the contribution of circRNAs to osteosarcoma remains largely unclear. Results indicated that expression of circATRNL1 was higher in osteosarcoma tissues and cells. The high-expression of circATRNL1 was significantly correlated with aggressive features and acted as an independent risk factor for osteosarcoma patients' overall survival. Functionally, our findings demonstrate that circATRNL1 promotes the osteosarcoma aerobic glycolysis in vitro. Mechanistically, circATRNL1 up-regulated the expression level of LDHA, which was also targeted by miR-409-3p. Therefore, circATRNL1 exerted the accelerative roles of osteosarcoma aerobic glycolysis through miR-409-3p/LDHA axis. In conclusion, circATRNL1 promoted osteosarcoma progression by enhancing glycolysis via circATRNL1/miR-409-3p/LDHA axis, which may inspire a novel therapeutic target for osteosarcoma.
Collapse
Affiliation(s)
- Quanbin Zhang
- Department of Orthopedics, Zibo Central Hospital, Zibo Hospital Affiliated to Shandong First Medical University, Zibo, China
| | - Lina Wang
- Department of Clinical Laboratory, The Fifth People’s Hospital of Zibo City, Zibo, China
| | - Lili Cao
- Department of Oncology, Zibo Central Hospital, Zibo Hospital Affiliated to Shandong First Medical University, Zibo, China
| | - Tao Wei
- Department of Orthopedics, Zibo Central Hospital, Zibo Hospital Affiliated to Shandong First Medical University, Zibo, China
| |
Collapse
|